Home/Pipeline/ANKTIVA-based regimens

ANKTIVA-based regimens

HIV

Phase 1/2Active

Key Facts

Indication

HIV

Phase

Phase 1/2

Status

Active

Company

ImmunityBio

About ImmunityBio

ImmunityBio is a clinical-stage biotech focused on developing a 'Cancer BioShield' through its proprietary immunotherapy platforms, including the IL-15 superagonist ANKTIVA® and off-the-shelf NK cell therapies. The company's core mission is to defeat cancer and infectious diseases by enhancing, rather than weakening, the patient's immune system. Its first FDA approval in 2024 for bladder cancer validates its scientific approach and provides a commercial foundation for expanding into multiple solid tumor and infectious disease indications.

View full company profile

Therapeutic Areas

Bladder Cancer Non-Small Cell Lung Cancer Glioblastoma Lynch Syndrome Non-Hodgkin Lymphoma Ovarian Cancer HIV

Other HIV Drugs

Drug	Company	Phase	Status
NanoDDI	Continuity Biosciences	Pre-clinical	Active
HIV Gene Therapy	Nanite	Pre-clinical	Active
RGFields for HIV	Anapole Technologies	Clinical (phase unspecified)	Active
HIV mAb Program	Adnexus	Pre-clinical	Active
Undisclosed Program	EnnoDC	Phase 1	Active
O2-16 Series	OyaGen	Preclinical	Active
SBX 2048	Stramsen Biotech	Early-stage Clinical	Active
Undisclosed Candidates	Brii Biosciences	Phase 1	Active
ALF Platform	Senzo	Pre-clinical	Active
Gilead HIV Franchise	Royalty Pharma	Marketed	Active